In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Thanks to 3D printing technology, a bioengineer at the McGill University Health Centre is taking personalized health care to a whole new level. Lung regenerative medicine specialist Darcy Wagner and ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

A Firestorm xCell micro 3D printing factory loading onto a C-130 to print Tempest UAV systems at a U.S. Air Force base. Inside a standard shipping container, a "factory-in-a-box" hums to life. It is ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Kathleen Elkins Every time Kathleen publishes a story, you’ll get an alert straight to your ...